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Treatment of intact human platelets and S49 lymphoma cyc- cells with the phorbol ester, 12-O-tetradeca- 
noylphorbol- 13-acetate, impairs GTP-dependent and hormone-induced inhibition of adenylate cyclase, an 
action mediated by the inhibitory coupling protein N,. In contrast, r~eptor-inde~ndent activation of N, 
with subsequent adenylate cyclase inhibition induced by the stable GTP analog, guanosine S-[y-thio]tri- 
phosphate, was affected in neither the potency nor onset of N, activation by the stable GTP analog, in both 
membrane systems tudied. The data indicate that moditication of N, following phorbol ester treatment does 
not impair its activation by stable GTP analogs. 
Adenylate cyclase Inhibitory coupling protein N, Phorbol ester Protein kinase C 
Inhibitory h&none G TP analog 
1. INTRODUCTION 
We have recently reported that treatment of in- 
tact human platelets and S49 lymphoma cyc- cells 
with the phorbol ester, f2-O-tetradecanoyl- 
phorbol-13-acetate (TPA), impairs inhibition of 
adenylate cyclase by hormonal factors [ 1,2]. Fur- 
thermore, a similar effect with regard to impair- 
ment of GTP-dependent and hormone-induced in- 
hibition of adenylate cyclase was observed when 
purified, Ca*+ -activated, phospholipid-dependent 
protein kinase (protein kinase C) [3] was added to 
membranes of human platelets [4]. Finally, partial- 
ly purified protein kinase C was shown to phos- 
phorylate the guanine nucleotide-binding a-sub- 
unit of the inhibitory coupling protein Ni of the 
adenylate cyclase system [2]. This phosphorylation 
was observed with the purified Ni component and 
apparently also with the Ni protein present in in- 
tact and solubilized platelet membranes [2]. These 
data suggest hat phosphorylation of Ni by protein 
kinase C impairs its function in the inhibitory hor- 
mone signal transduction to the adenylate cyclase. 
by stable GTI? analogs such as guanosine 5 ‘-[y- 
thioltriphosphate (GTP[S]) and guanosine 5’-[p,y- 
imidoltriphosphate even without hormones pre- 
sent. Such an activation of Ni has been observed in 
various membrane systems, including those of 
human platelets and S49 lymphoma cyc- cells 
[5-71. Activation of Ni with subsequent inhibition 
of adenylate cyclase by stable GTP analogs is 
preceded by a considerable lag phase, which is not 
seen with inhibitory hormones and GTP [5-71. 
Therefore, we investigated whether treatment of 
intact human platelets and 549 lymphoma cyc- 
cells with TPA may also affect the receptor- 
independent activation of Ni by stable GTP 
analogs. We report here that, in contrast to 
hormone-induced inhibition of adenylate cyclase, 
inhibition of adenylate cyclase by the stable GTP 
analog GTP[S] is not impaired by the phorbol ester 
treatment. 
2. MATERIALS AND METHODS 
In addition to being activated by agonist- 
stimulated hormone receptors in the presence of 
GTP, the Ni component can be directly activated 
GTP[S] was obtained from Boehringer Mann- 
heim. The other materials used were from 
previously described sources [1,2,4]. Pretreatment 
of intact human platelets and S49 lymphoma cyc- 
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cells with TPA at 1 pM was carried out as in [I ,2]. 
Preparation of membranes from control and TPA- 
pretreated cells was performed as in f5,7]. 
Adenylate cyclase activity of human platelet 
membranes (3-5 ,ug protein/tube) was determined 
with a reaction mixture containing 50 yM [LY-~~P]- 
ATP (0.2-0.3 &i/tube), 2 mM MgC12, 0.1 mM 
EGTA, I mM 3-isobutyl-l-methylxanthine, 0.1 
mM cyclic AMP, 1 mM dithiothreitol, 5 mM 
creatine phosphate, 0.4 mgfml creatine kinase, 
2 mg/ml bovine serum albumin, 20/1M forskolin 
and the additions indicated in 50 mM triethanol- 
amine-HCI, pH 7.4, in a total volume of 100~1. 
For measurement of adenylate cyclase activity in 
membranes of 549 lymphoma cyc- cells (15-25 yg 
protein/tube), the reaction mixture was the same 
as that above with the exceptions that MgC12 was 
replaced by 200 /IM MnClz and EGTA was omit- 
ted. Furthermore, the concentration of forskolin 
was IOOpM. The membranes were preincubated 
with the complete reaction mixture including for- 
skolin and the GTP analog for 10 min at 25°C to 
overcome the lag phase of GTP[S]. Thereafter, 
measurement of adenylate cyclase activity was 
started by addition of labelled ATP and conducted 
for 10 min at 25°C. In time course experiments, 
the membranes were preincubated for 7 min at 
2YC with the reaction mixture including forskolin 
but without GTP[S] present. This preincubation 
was necessary in order to have linear rates of cyclic 
AMP formation, since the stimulatory effect of 
forskolin, the presence of which was required to 
observe the inhibition by GTP[S], is also preceded 
by a short lag period [5]. Measurement of cyclic 
AMP accumulation was initiated by the addition 
of [LU-~~P]ATP without and with GTP[S] and con- 
tinued for various time periods at 25°C. Stopping 
of the reaction and isolation of cyclic AMP formed 
were as in [8]. The assays were performed in 
triplicate with an intra-assay variation of less than 
5% of the means and were repeated twice with 
results comparable to those shown herein. 
3. RESULTS 
As shown before [l], treatment of human 
platelets with the phorbol ester TPA (1 PM) 
resulted in a large reduction in adenylate cyclase 
inhibition caused by the inhibitory hormone 
epinephrine, as measured in membrane prepara- 
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tions in the presence of 10 PM GTP (fig. 1). In con- 
trol membranes, epinephrine reduced enzyme ac- 
tivity by 40-50%. In membranes of platelets pre- 
treated with TPA, epinephrine-induced adenylate 
cyclase inhibition was only observed at high 
agonist concentrations with a marked reduction in 
the maximal extent of inhibition. In contrast, in- 
hibition of the forskolin-stimulated platelet 
adenylate cyclase by the stable GTP analog 
GTP[S] appeared not to be affected by the phorbol 
ester treatment. Both the maximal extent of inhibi- 
tion and the potency of GTP[S] were very similar 
in control membranes and membranes of human 
platelets pretreated with TPA. 
The stable GTP analog-induced inhibition of 
adenylate cyclase is preceded by a considerable lag 
phase, the duration of which is inversely related to 
the GTP[S] concentration [5] and which appears to 
reflect the time required to activate Ni fully. There- 
fore, we studied whether the TPA treatment may 
affect this turn-on reaction of Ni by GTP[S]. As 
GTP[S] or Epinephrine (log Ml 
Fig-l. Influence of TPA treatment of intact human 
platelets on hormone- and GTP[S]-induced inhibition of 
adenyIate cyclase. In membranes of control platelets 
(closed symbols) and platelets treated with 1 ,&I TPA 
(open symbols), adenyIate cyclase activity was deter- 
mined as described in section 2 at the indicated concen- 
trations of epinephrine (=, 0) or GTP[S] (*,O). For 
study of the effect of epinephrine, GTP (IO PM) was in- 
cluded in the reaction mixture. Adenylate cyclase activi- 
ty is given as percent of control activities measured in the 
absence of epinephrine and GTP(S]. 
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shown in fig.2, in control membr~es inhibition of 
cyclic AMP fortnation by the adenylate cyclase 
caused by the addition of GTPfS] (30 nM) was 
preceded by a small but significant lag phase of 
about 2.5 min at 25°C. The maximal extent of in- 
hibition achieved was 65-70%. In membranes pre- 
treated with TPA (I pM), control forskolin- 
stimulated activity was increased somewhat, by 
about lWo, as reported in [l]. As in Cpntrol mem- 
branes, the inhibition of cyclic AMP formation in 
membr~es of TPA-pretreated plateIets induced 
by GTPiS] was preceded by a lag phase, the dura- 
tion of which (2.1 min) was similar to that ob- 
served in control membranes. Furthermore, the 
maximal extent of inhibition caused by GTPfS] 
was identical in control membranes and mem- 
branes of TPA-pretreated platelets, 
In membranes of S49 lymphoma cyc- variants, 
which lack the guanine nucleotide-binding m-sub- 
unit of the stimulatory coupling component N, [9], 
stable GTP analogs apparently only interact with 
the Ni component causing adenylate cyclase inhibi- 
incubation time (mid 
Fig.2. Time course of GTP[S]-induced inhibition of 
adeuylate cycIase in membranes of control and TPA- 
pretreated platelets. Cyclic AMP accumulation was 
studied in membranes of control (open symbols) and 
TPA-treated platelets (closed symbols) in the absence 
fO,a) and presence of 30 nM GTPIS] (o,m) for the in- 
dicated periods of time. GTPIS] was added to the reac- 
tion at zero time. The intercepts of the control curves 
(5,o) with the dashed Imes indicate the extrapolated 
time lags of GTP[S] action. 
50 I 
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Fig.3. Influence af TPA treatment of intact S49 lym- 
phoma cyc- cells on GTP[S]-induced inhibition of 
adenylate cyclase. Adenylate cyclase activity was deter- 
mined in membranes of contro1 (0) and TPA (1 pM)- 
pretreated (e) 549 lymphoma cyc- cells at the indicated 
concentrations of GTPIS] as described in section 2. 
tion {6,?]. It has been shown that, similarly to 
human platelets, treatment of intact S49 lym- 
phoma cyc- cells with TPA impairs GTP- 
dependent inhibition of adenylate cyclase by the 
inhibitory hormone, somatostatin, whereas activa- 
tion of adenylate cyclase by forskolin is apparently 
not affected [2]. Therefore, we also determined 
whether the receptor-independent activation of Ni 
by GTP[S] with subsequent inhibition of adenylate 
cyclase is affected by the phorbol ester treatment, 
As shown in fig.3, in membranes of control 549 
lymphoma cyc- cells, GTP[S] reduced adenylate 
cyclase activity by maximally 40% ) with an XC& of 
about 10 nM, In membranes of S49 lymphoma 
cyc- cehs pretreated with TPA (1 FM), a treatment 
which impaired somatostatin-induced inhibition 
[2], both the potency and efficiency of GTP[S] in 
causing inhibition of adenylate cyclase were iden- 
tical to those in control membranes. 
4. DISCUSSION 
Treatment of intact human platelets artd 549 
lymphoma cyc” cells with the phorbol ester TPA 
inhibits GTP~depe~de~t and ho~one~indu~ed in- 
45 
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hibition of adenylate cyclase, a reaction mediated 
by the inhibitory coupling protein Ni [1,2]. This 
impairment seems to be due to phosphorylation of 
the guanine nucleotide-binding a-subunit of Ni by 
TPA-activated protein kinase C [2]. In this regard, 
the action of TPA appears to be similar to that of 
pertussis toxin, causing ADP-ribosylation of the ar- 
subunit of Ni [lo,1 l] with subsequent impairment 
of the inhibitory hormone signal transduction to 
the adenylate cyclase [12]. Furthermore, as in the 
case shown here for membranes of TPA-treated 
cells, treatment with pertussis toxin does not 
abolish Ni-mediated inhibition of adenylate cyclase 
by stable GTP analogs [13-151. However, treat- 
ment with pertussis toxin causes a large increase in 
the lag phase of GTP[S] inhibitory action, sug- 
gesting that the activation of Ni is impaired by its 
ADP-ribosylation [16]. In contrast, as shown here 
for membranes of TPA-treated platelets, the phor- 
bol ester treatment did not cause an increase in the 
lag phase of the inhibitory action of GTP[S]. 
These data suggest that, in contrast to pertussis 
toxin-ADP-ribosylated Ni, phosphorylation of Ni 
by protein kinase C does not impair the activation 
process of Ni following binding of stable GTP 
analogs. In this regard, it is worth bearing in mind 
that both ADP-ribosylation and phosphorylation 
of Ni by pertussis toxin and protein kinase C, 
respectively, are inhibited by pretreatment with 
GTP[S] [2,17]. However, whereas ADP- 
ribosylation of mt depends on the presence of the 
.&-subunit complex, phosphorylation of ai by pro- 
tein kinase C is inhibited by this complex [2,18]. 
If, as suggested by the present data, the activa- 
tion reaction of Ni is not inhibited following 
phosphorylation by protein kinase C, it may be 
speculated that the inactivation reaction of Ni ap- 
parently involving hydrolysis of cur-bound GTP to 
GDP and association of cy- and &subunits is in- 
creased. Such an increased hydroiysis of GTP 
would not affect the action of stable GTP anaIogs. 
It is also feasible that Ni phosphorylated by protein 
kinase C hydrolyzes GTP to GDP before the com- 
ponent can isomerize to the active state. Since GTP 
is required for the active state, this state will not be 
formed in an amount sufficient to induce inhibi- 
tion of adenylate cyclase. Such a premature 
hydrolysis of GTP would also not affect the activa- 
tion reaction of Ni by stable GTP analogs. Finally, 
is has not been proven that the mechanism of Ni 
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activation by stable GTP analogs such as GTP(S] 
is identical to that caused by GTP and agonist- 
activated hormone receptors. 
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